GSK India: What would it look like - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK India: What would it look like

Oct 25, 2001

Glaxo India has just declared its financial results for nine months ended 30th September’01. As the merger of the company with SmithKline Pharma became effective from the beginning of the calendar year, the performance of the company is inclusive with that of SmithKline Beecham Pharma Ltd. On a merged basis, the company declared a drop in turnover by around 13% and drop in PBT by around 36%. Operating margins are finding difficult to cross the double-digit mark.

  • Click here for detailed financial performance.

    Apart from sluggish domestic pharma market, the poor performance of the company has been due to three major reasons:

    • Both the companies initiated a major rejuvenation to align their product portfolio and focus on high margin products. In this exercise, Glaxo did away with a number of low margin products.

    • Glaxo India also undertook a restructuring exercise in terms of shifting its manufacturing base from high cost centers, strategic change in sales and marketing structure and higher focus on creating brands. The sales division of the company was changed to ‘therapy focused’ marketing.

    • Glaxo declared a major VRS drive to achieve operational cost benefits with that of SmithKline Pharma. It also attempted to restructure salary structure differences between the two organisations to achieve smooth integration.

    The company has already incurred VRS and integration/restructuring activities related cost of Rs 80 m and Rs 102 m respectively, till date. The company is expected to incur an additional VRS cost of Rs 750 m on its Worli factory in the coming quarters.

    A new entity Glaxo SmithKline Beecham Ltd (GSK) will be created and soon be listed on the bourses. The shareholders of Glaxo and SmithKline would be allotted shares in GSK Ltd in the ratio of 2:1 (i.e. 1 share of Glaxo= 1 share of GSK and 2 share of SmithKline = 1 share of GSK Ltd). The merger would become effective on the BSE on November 9, 2001.

    Assuming that additional VRS expenses would be incurred in FY02 in the books of GSK India and excluding any extra-ordinary gains from sale of property, GSK’s snapshot can be depicted as shown in the table below.

    GSK India - What would it look like
      FY02E FY03E
    Sales (Rs m) 11,050 12,089
    Net Profit (Rs m)* 54 896
    Expected EPS (Rs) 0.7 12
    Current Market Cap. (Rs m) 18,829  
    Market Cap/Sales 1.7 1.6
    (* After deducting Rs 750 m on account of expected VRS expenses)

    In the near term, the financials of the company are expected to suffer from the integration pain. Also, the operational cost benefits from the merger are expected to take time before they become visible.

  • Equitymaster requests your view! Post a comment on "GSK India: What would it look like". Click here!

      

    More Views on News

    GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

    Feb 10, 2021 | Updated on Feb 10, 2021

    For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

    GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

    Oct 30, 2020 | Updated on Oct 30, 2020

    For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

    Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

    Jun 15, 2021

    All you need to know about the IPO of Krishna Institute of Medical Sciences.

    Why Did Shares of Divi's Lab Rally Today? (Views On News)

    Jun 10, 2021

    The stock jumped 3.6% in intraday trade to hit its 52-week high.

    Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

    Jun 8, 2021

    Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

    More Views on News

    Most Popular

    Hotel Stocks Will Reward Investors (Fast Profits Daily)

    Jun 8, 2021

    This is why I'm bullish on the hotel and hospitality sector.

    My 'Unlock' Investments (Fast Profits Daily)

    Jun 11, 2021

    The best unlock investments you can make in the market.

    The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

    Jun 9, 2021

    Investing in the best stocks could result in wealth compounding on a massive scale.

    How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

    Jun 11, 2021

    Charlie Munger's open secret about investing success.

    More

    India's #1 Trader
    Reveals His Secrets

    Secret To Increasing Your Trading Profits Today
    Get this Special Report,
    The Secret to Increasing Your Trading Profits Today, Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Jun 18, 2021 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA - TEVA PHARMA COMPARISON

    COMPARE GSK PHARMA WITH

    MARKET STATS